Ovid Therapeutics Inc.
OVID
$1.56
-$0.01-0.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.61M | 6.65M | 548.00K | 566.00K | 632.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.61M | 6.65M | 548.00K | 566.00K | 632.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.61M | 6.65M | 548.00K | 566.00K | 632.00K |
| SG&A Expenses | 24.46M | 23.22M | 26.44M | 27.59M | 27.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.68M | 48.42M | 57.76M | 62.65M | 68.28M |
| Operating Income | -41.07M | -41.77M | -57.22M | -62.08M | -67.65M |
| Income Before Tax | -36.33M | -38.18M | -24.97M | -26.43M | -32.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.33 | -38.18 | -24.97 | -26.43 | -32.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.33M | -38.18M | -24.97M | -26.43M | -32.50M |
| EBIT | -41.07M | -41.77M | -57.22M | -62.08M | -67.65M |
| EBITDA | -40.65M | -41.20M | -56.60M | -61.47M | -67.06M |
| EPS Basic | -0.50 | -0.53 | -0.34 | -0.37 | -0.45 |
| Normalized Basic EPS | -0.34 | -0.35 | -0.25 | -0.28 | -0.33 |
| EPS Diluted | -0.50 | -0.53 | -0.35 | -0.37 | -0.45 |
| Normalized Diluted EPS | -0.34 | -0.35 | -0.25 | -0.28 | -0.33 |
| Average Basic Shares Outstanding | 284.28M | 284.14M | 283.95M | 283.62M | 283.30M |
| Average Diluted Shares Outstanding | 284.28M | 284.14M | 284.23M | 283.90M | 283.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |